Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Aura Biosciences, Inc.

AURA · Nasdaq · CIK 0001501796 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

15 Form 4 transaction lines observed in the same window
2 sales · 13 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-16 · Johnson David Michael · $98.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Gibney Anthony SSee Remarks
▼
Bitetti Teresa MarieDirector
○
Srivastava SapnaDirector
○
Johnson David MichaelDirector
○
Mattessich Antony C.Director
○
Holles Natalie C.See Remarks
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 8 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-16 · Johnson David Michael.

Recent Form 4 activity

0Purchases
13Sales
19Other Form 4 lines
31SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER13 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-6.4%
3M
-6.6%
6M
-3.8%
12M
+7.4%

Volatility & liquidity

Volatility
58.3%
Beta
—
Avg daily value
USD 5.0M

Valuation

Market cap
USD 678.2M
P/E
—

Fundamentals

Profit margin
—
ROE
-77.6%
Industry
Biotechnology

Market data

Price data up to: 2026-10-09 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
10,366,122
Previous report
7,049,973
Avg daily volume
1,122,555
Days to cover
9.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-16Johnson David MichaelPurchase (P)Common Stock20,000USD 4.90USD 98,000SEC filing ↗
2025-05-16Gibney Anthony SPurchase (P)Common Stock50,000USD 4.90USD 245,000SEC filing ↗
2023-11-09GOEL DAVID E.; Matrix Capital Management Company, LPPurchase (P)Common Stock, par value $0.00001 per share (Common Stock)1,560,000USD 9.00USD 14,040,000SEC filing ↗
2023-11-08Johnson David MichaelPurchase (P)Common Stock19,601USD 7.30USD 143,087SEC filing ↗
2023-11-07Johnson David MichaelPurchase (P)Common Stock123,000USD 7.17USD 881,910SEC filing ↗
2023-10-04Johnson David MichaelPurchase (P)Common Stock6,566USD 8.61USD 56,533SEC filing ↗
2023-10-03Johnson David MichaelPurchase (P)Common Stock13,500USD 8.27USD 111,645SEC filing ↗
2023-01-06Johnson David MichaelPurchase (P)Common Stock1,604USD 10.51USD 16,851SEC filing ↗
2023-01-05Johnson David MichaelPurchase (P)Common Stock396USD 10.00USD 3,960SEC filing ↗
2022-12-28Johnson David MichaelPurchase (P)Common Stock2,000USD 9.75USD 19,500SEC filing ↗
2022-12-05GOEL DAVID E.; Matrix Capital Management Company, LPPurchase (P)Common Stock, par value $0.00001 per share ("Common Stock")1,250,000USD 12.00USD 15,000,000SEC filing ↗
2022-12-01Johnson David MichaelPurchase (P)Common Stock5,000USD 12.37USD 61,850SEC filing ↗
2022-06-13Johnson David MichaelPurchase (P)Common Stock27,000USD 13.99USD 377,730SEC filing ↗
2022-06-10Johnson David MichaelPurchase (P)Common Stock13,000USD 15.04USD 195,520SEC filing ↗
2021-11-02Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) LtdPurchase (P)Common Stock710,000USD 14.00USD 9,940,000SEC filing ↗

Form 4 evidence

32 transaction lines in the latest 365-day window; 130 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Person JulieAward / grant (A)Common Stock107,611USD 0.00USD 0SEC filing ↗
2026-09-01Kratz EricaAward / grant (A)Common Stock100,885USD 0.00USD 0SEC filing ↗
2026-09-01Hopkins Janet JillAward / grant (A)Common Stock58,850USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Person JulieAward / grant (A)Common Stock107,611USD 0.00USD 0SEC filing ↗
2026-09-01Kratz EricaAward / grant (A)Common Stock100,885USD 0.00USD 0SEC filing ↗
2026-09-01Hopkins Janet JillAward / grant (A)Common Stock58,850USD 0.00USD 0SEC filing ↗
2026-09-01Elazzouzi AmyAward / grant (A)Common Stock23,540USD 0.00USD 0SEC filing ↗
2026-09-01Abu-Absi SusanAward / grant (A)Common Stock134,513USD 0.00USD 0SEC filing ↗
2026-07-07Bender JeremyAward / grant (A)Common Stock30,000USD 0.00USD 0SEC filing ↗
2026-07-01Kilroy ConorAward / grant (A)Common Stock14,858USD 0.00USD 0SEC filing ↗
2026-06-16Gibney Anthony SSale (S)Common Stock12,824USD 6.42USD 82,330SEC filing ↗
2026-06-11Srivastava SapnaAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-06-11Mattessich Antony C.Award / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-06-11Johnson David MichaelAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-06-11Bitetti Teresa MarieAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-05-19Holles Natalie C.Award / grant (A)Common Stock1,153,962USD 0.00USD 0SEC filing ↗
2026-05-07GOEL DAVID E.; Matrix Capital Management Company, LPSale (S)Common Stock, par value $0.00001 per share (Common Stock)6,922,870USD 5.64USD 39,044,987SEC filing ↗
2026-04-16Kilroy ConorSale (S)Common Stock11,738USD 7.02USD 82,401SEC filing ↗
2026-03-02de los Pinos ElisabetAward / grant (A)Common Stock166,000USD 0.00USD 0SEC filing ↗
2026-03-02Plavsic MarkAward / grant (A)Common Stock62,339USD 0.00USD 0SEC filing ↗
2026-03-02Kilroy ConorAward / grant (A)Common Stock62,339USD 0.00USD 0SEC filing ↗
2026-03-02Hopkins Janet JillAward / grant (A)Common Stock89,056USD 0.00USD 0SEC filing ↗
2026-03-02Gibney Anthony SAward / grant (A)Common Stock71,245USD 0.00USD 0SEC filing ↗
2026-03-02Elazzouzi AmyAward / grant (A)Common Stock44,528USD 0.00USD 0SEC filing ↗
2026-02-17de los Pinos ElisabetSale (S)Common Stock47,648USD 5.06USD 241,099SEC filing ↗
2026-02-17Plavsic MarkSale (S)Common Stock15,890USD 5.05USD 80,244SEC filing ↗
2026-02-17Kilroy ConorSale (S)Common Stock12,079USD 5.05USD 60,999SEC filing ↗
2026-02-17Hopkins Janet JillSale (S)Common Stock20,401USD 5.06USD 103,229SEC filing ↗
2026-02-17Elazzouzi AmySale (S)Common Stock8,549USD 5.06USD 43,258SEC filing ↗
2026-01-20de los Pinos ElisabetSale (S)Common Stock16,928USD 4.86USD 82,270SEC filing ↗
2026-01-20Elazzouzi AmySale (S)Common Stock1,581USD 4.86USD 7,684SEC filing ↗
2025-11-17Hopkins Janet JillSale (S)Common Stock17,109USD 5.42USD 92,731SEC filing ↗
2025-10-29de los Pinos ElisabetSale (S)Common Stock9,049USD 6.35USD 57,461SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAURA
CIK0001501796
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history130 transaction lines from 2021-10-28 to 2026-09-01
23 P purchase lines · 40 S sale lines · 67 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.